Literature DB >> 15623705

Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis.

Susanne Gaertner1, Katrien L de Graaf, Bernhard Greve, Robert Weissert.   

Abstract

Antibodies against native glycosylated myelin-oligodendrocyte-glycoprotein (MOG) were measured by ELISA in patients with multiple sclerosis (MS) and controls. Anti-MOG IgM antibodies were elevated during the first demyelinating event. Higher MOG-specific IgG antibodies were found in patients during relapses and in secondary chronic progressive MS compared to patients in remission and healthy controls. Antibodies against native MOG may be a potential biomarker for MS.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15623705     DOI： 10.1212/01.wnl.0000147259.34163.33

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  17 in total

1.  Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.

Authors:  Marie Cathrin Mayer; Edgar Meinl
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

Review 2.  B-cells and humoral immunity in multiple sclerosis. Implications for therapy.

Authors:  Sangjin Oh; Cornelia Cudrici; Takahiro Ito; Horea Rus
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

3.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

4.  An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis.

Authors:  Francesco Lolli; Barbara Mulinacci; Alfonso Carotenuto; Bruno Bonetti; Giuseppina Sabatino; Benedetta Mazzanti; Anna Maria D'Ursi; Ettore Novellino; Marta Pazzagli; Laura Lovato; Maria C Alcaro; Elisa Peroni; Maria C Pozo-Carrero; Francesca Nuti; Luca Battistini; Giovanna Borsellino; Mario Chelli; Paolo Rovero; Anna Maria Papini
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-12       Impact factor: 11.205

5.  Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis.

Authors:  Eric C Klawiter; Laura Piccio; Jeri-Anne Lyons; Robert Mikesell; Kevin C O'Connor; Anne H Cross
Journal:  Arch Neurol       Date:  2010-09

6.  [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].

Authors:  Peter Rieckmann
Journal:  Nervenarzt       Date:  2006-12       Impact factor: 1.214

7.  Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF.

Authors:  Jens Kuhle; Raija L P Lindberg; Axel Regeniter; Matthias Mehling; Francine Hoffmann; Markus Reindl; Thomas Berger; Ernst W Radue; David Leppert; Ludwig Kappos
Journal:  J Neurol       Date:  2007-02       Impact factor: 4.849

8.  Autoantigen conformation influences both B- and T-cell responses and encephalitogenicity.

Authors:  Katrien L de Graaf; Monika Albert; Robert Weissert
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

9.  Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis.

Authors:  Patrice H Lalive; Til Menge; Cecile Delarasse; Bruno Della Gaspera; Danielle Pham-Dinh; Pablo Villoslada; H-C von Büdingen; Claude P Genain
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

Review 10.  MicroRNAs as novel regulators of neuroinflammation.

Authors:  Dominika Justyna Ksiazek-Winiarek; Magdalena Justyna Kacperska; Andrzej Glabinski
Journal:  Mediators Inflamm       Date:  2013-07-25       Impact factor: 4.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.